Get the Stockscreener App
8.10
1.22%
-0.10
After Hours:
8.17
0.07
+0.86%
Immunitybio Inc stock is traded at $8.10, with a volume of 13.12M.
It is down -1.22% in the last 24 hours and down -4.37% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.20
Open:
$8.37
24h Volume:
13.12M
Relative Volume:
0.36
Market Cap:
$8.37B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-20.78
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
+6.58%
1M Performance:
-4.37%
6M Performance:
+231.97%
1Y Performance:
+222.71%
1-Day Range:
$7.9801
$8.56
1-Week Range:
$7.12
$8.56
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.10 | 8.47B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
436.59 | 111.71B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.36 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
805.38 | 51.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.43 | 41.49B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.31 | 35.31B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX - FinancialContent
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Jim Cramer Suggests Waiting for Clarity on ImmunityBio Before Taking a “Hard Look” - Insider Monkey
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - PR Newswire
Avis Brings Back The Short Squeeze — Navitas, Beyond Meat Join In - Benzinga
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline - TMX Newsfile
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia - Benzinga
IBRX Stock Has Quadrupled This Year – And Its Breakout Cancer Drug Has Hit A New Market - Stocktwits
IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
ImmunityBio’s Anktiva launches commercially in Saudi Arabia - Investing.com
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership - ImmunityBio
ImmunityBio (IBRX) Is Up 12.3% After 168% Surge In Q1 2026 Preliminary RevenueWhat's Changed - simplywall.st
IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal - Stocktwits
Deadline Approaching for Investors of ImmunityBio, Inc. (NASDAQ: IBRX)Contact Kaplan Fox Before May 26, 2026 - NewMediaWire
ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says - Law360
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - GlobeNewswire
ImmunityBio Inc stock (US45258J1025): Is its immunotherapy pipeline strong enough to unlock new upsi - AD HOC NEWS
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential - GlobeNewswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with - GlobeNewswire
ImmunityBio, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsIBRX - Lelezard
ImmunityBio Inc stock (US45258J1025): Is its cancer immunotherapy platform strong enough to unlock n - AD HOC NEWS
ImmunityBio's Legal Deadline and Record Revenue Collide - AD HOC NEWS
IBRX Founder Backs Trump’s Psychedelic Push In ‘Transforming’ Health Policy — Flags New Anktiva Breast Cancer Risk Data - Stocktwits
ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - The Globe and Mail
Lobbying Update: $60,000 of IMMUNITYBIO INC. lobbying was just disclosed - Quiver Quantitative
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WFXG
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) posts strong preliminary Q1 sales on ANKTIVA momentum - MSN
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit - NewMediaWire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securi - GuruFocus
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - The Spec
Deadline to Lead in Securities Class Action Against ImmunityBio - The National Law Review
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights - The Daily Tribune News
Deadline to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026Contact Kaplan Fox - The Globe and Mail
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses ... - Bluefield Daily Telegraph
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — Hagens Berman - Morningstar
Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (IBRX) Global Expansion Bolsters 266% Jump This Year - Yahoo Finance
2026-04-17 | IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:IBRX | Press Release - Stockhouse
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):